Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 749-759

  Cernes, Relu ^a   Mashavi, Margarita ^a   Zimlichman, Reuven ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Angiotensin receptor blockers; Blood pressure; Candesartan; Candesartan cilexetil; Clinical trials; Efficacy studies; Safety

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; CREATININE; TETRAZOLE DERIVATIVE;

ALBUMINURIA; ARTERY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; ELASTICITY; HEART STROKE VOLUME; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS (TOPIC); MIGRAINE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; REVIEW;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARTERIES; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CREATININE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ELASTICITY; HUMANS; KIDNEY TRANSPLANTATION; META-ANALYSIS AS TOPIC; MIGRAINE DISORDERS; PROTEINURIA; STROKE VOLUME; TETRAZOLES;

EID: 84861656706     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S22591     Document Type: Review

References (44)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480-486.
2. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
3. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;(4):CD003822.
4. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68:1207-1225.
5. Mizuno K, Niimura S, Tani M, et al. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci. 1992;51:PL183-187.
6. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther. 1994;16:74-86.
7. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokineticpharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet. 1997;32:1-29.
8. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin system control. J Hum Hypertens. 1993; 7(Suppl 2):S19-S31.
9. Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T. Pharmacologic properties of candesartan cilexetil-possible mechanisms of long-acting antihypertensive action. J Hum Hypertens. 1999;13(Suppl 1):S75-S80.
10. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302:237-243.
11. Yasuda N, Miura S, Akazawa H, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep. 2008;9:179-186.
12. Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1-7.
13. Munger MA. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P.T. 2011;36: 22-40.
14. Benson SC, Pershadsingh HA, Ho CI, et al. Identif ication of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993-1002.
15. Barra S, Vitagliano A, Cuomo V, Vitagliano G, Gaeta G. Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opin Pharmacother. 2009;10:173-189.
16. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
17. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
18. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
19. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.
20. Féghali RE, Nisse-Durgeat S, Asmar R. Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. Vasc Health Risk Manag. 2007;3:165-171.
21. Ozaki N, Nomura Y, Sobajima H, Kondo K, Oiso Y. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med. 2010;21:236-239.
22. Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical-and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta-and cost-utility analysis. Int J Clin Pract. 2011;65:253-263.
23. Knudsen ST, Andersen NH, Poulsen SH, et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am J Hypertens. 2008;21:172-176.
24. Shargorodsky M, Hass E, Boaz M, Gavish D, Zimlichman R. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis. 2008;197:303-310.
25. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25:967-976.
26. Tamura Y, Kosuga M, Yamashita M, et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol. 2008; 12:256-263.
27. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care. 2003;26:150-155.
28. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
29. Schrader J, Lüders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34:1699-1703.
30. Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741-750.
31. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394-1402.
32. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-1393.
33. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51:393-398.
34. Nakao K, Hirata M, Oba K, et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res. 2010;33:600-606.
35. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotension II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
36. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473-479.
37. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
38. Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007;50:1959-1966.
39. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens. 2002;16:795-803.
40. Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006;29:2210-2217.
41. Porta M, Hainer JW, Jansson SO, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia. 2011;54:1298-1303.
42. Schaefer F, van de Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083-1090.
43. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008;10:743-750.
44. Connolly S, Yusuf S, Swedberg K, et al. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623-635.